GlassScriptPhysician profile
Kimberlee A Wilcox
NPI 1427142140
$7,785.34
in general payments reported to CMS, 2019-2025
31 companies · $2,122 in 2025
The $2,122 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,439 · 2022: $1,327 · 2023: $1,580 · 2024: $1,318 · 2025: $2,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,009 · Education: $10.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,009.48 |
| Education | $10.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,077.64 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $727.11 | 2022-2025 | Lifevest |
| Boston Scientific Corporation | $693.51 | 2021-2025 | General - Therapies, Watchman Access System, Latitude Communicator Power Supply |
| Cvrx, INC. | $633.87 | 2021-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $483.58 | 2021-2025 | Airsupra, Farxiga |
| Abbott Laboratories | $461.21 | 2021-2023 | Coroflow, Mitraclip, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $420.75 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $315.63 | 2022-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $308.80 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $301.26 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $288.06 | 2022-2025 | Verquvo |
| Silk Road Medical, INC. | $258.74 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Alnylam Pharmaceuticals INC. | $231.99 | 2022-2025 | Amvuttra, Onpattro |
| Lundbeck LLC | $218.86 | 2025 | Vyepti, Rexulti |
| Acadia Pharmaceuticals INC | $198.12 | 2023 | Nuplazid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.03 | 2021-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $170.10 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $111.12 | 2021 | |
| Pulmonx Corporation | $110.45 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Esperion Therapeutics, INC. | $108.40 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $100.75 | 2021 | |
| Abbvie INC. | $95.92 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.82 | 2022 | |
| Atricure, INC. | $66.36 | 2024 | |
| Pfizer INC. | $47.80 | 2023-2025 | |
| Convatec INC. | $26.58 | 2022 | |
| Biotronik INC. | $25.28 | 2022 | |
| Chiesi USA, INC. | $16.22 | 2025 | Kengreal, Cleviprex |
| Regeneron Healthcare Solutions, INC. | $16.21 | 2025 | Evkeeza |
| Kestra Medical Technology Services, INC. | $15.82 | 2023 | Assure Wcd |
| Kowa Pharmaceuticals America, INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberlee Wilcox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.